| NCT ID | NCT05079399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Indiana University |
| Condition | Diabetic Retinopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 192 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 192 participants in total. It began in 2022-01-01 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.
Eligibility Criteria
Inclusion Criteria: * Ability to cooperate with imaging procedures. * Health status: established type 2 diabetes * No history of panretinal photocoagulation (PRP) * No history of treatment with intravitreal agents for past 12 months Exclusion Criteria: * Previous or current malignancy * Acute or chronic infection (HIV, hepatitis B or C, tuberculosis) * Cerebral vascular accident or cerebral vascular procedure * Current pregnancy * History of organ transplantation * Presence of a graft (to avoid any effect of the graft) * History of previous vitrectomy * Subjects with a history of age-related macular degeneration age-related macular degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05079399 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetic Retinopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05079399 currently recruiting?
Yes, NCT05079399 is actively recruiting participants. Contact the research team at abhatwad@iupui.edu for enrollment information.
Where is the NCT05079399 trial being conducted?
This trial is being conducted at Carmel, United States, Indianapolis, United States, Indianapolis, United States.
Who is sponsoring the NCT05079399 clinical trial?
NCT05079399 is sponsored by Indiana University. The trial plans to enroll 192 participants.